Curocell Inc.
Biotech developing enhanced CAR-T therapies for cancer using its OVIS™ platform.
372320 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 대전광역시 유성구 국제과학16로 11, 대전광역시
- Website:
- https://curocellbtx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Curocell Inc. is a clinical-stage biotechnology company specializing in the research and development of Chimeric Antigen Receptor T-cell (CAR-T) therapies for cancer. A pioneer in South Korea, the company developed Limkato, the nation's first CAR-T therapy to complete clinical trials and be submitted for regulatory approval. Curocell's key innovation is its proprietary OVIS™ platform technology, which is engineered to enhance the efficacy and persistence of CAR-T cells by overcoming immune checkpoint-induced exhaustion. The company aims to address the limitations of existing immunotherapies and provide new treatment options for cancer patients, supported by its state-of-the-art GMP manufacturing facility.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Curocell Inc. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all Curocell Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Curocell Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
